A Study Evaluating Disease Characteristics and Outcomes in Participants With Asthma in Routine Clinical Practice (AIRITY)
EU CTIS ID: 2025-524916-13-00
What this study is testing
Part 1: To describe the characteristics of participants with asthma across the spectrum of disease severity, including sociodemographic and clinical characteristics, treatment and disease burden, biomarkers, and both disease-specific and generic health-related quality of life Part 2: Two groups of prospective cohorts are defined based on: (A) Asthma control To describe long term asthma control and treatment patterns for asthma control cohorts (B) Type-2 biomarker levels To describe lung function longitudinally for Type-2 high and Type-2 low cohorts
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Applicable for Part 1 participants: 1) Age 6 years and older, at the time of signing the informed consent
- 2) Physician diagnosis of asthma for at least 12 months
- 3) Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- 4) Participant or legally authorized representative (where applicable) has consented to participate
- Applicable for Part 2 participants: 1) Age 18 years and older, at the time of signing the informed consent.
- 2) Physician diagnosis of asthma for at least 12 months
You likely can't join if
- Applicable for both Part 1 and Part 2 participants: 1) Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- 2) Participants with moderate/severe cognitive impairment.
- 3) Participants with moderate/severe cardiac disease.
- 4) Participants on immunosuppressive medication for a chronic condition
- 5) Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
See the full eligibility criteria
- Applicable for Part 1 participants: 1) Age 6 years and older, at the time of signing the informed consent
- 2) Physician diagnosis of asthma for at least 12 months
- 3) Existing treatment with low, medium, or high dose ICS and other asthma therapies as reflected in GINA 2-5 steps
- 4) Participant or legally authorized representative (where applicable) has consented to participate
- Applicable for Part 2 participants: 1) Age 18 years and older, at the time of signing the informed consent.
- 2) Physician diagnosis of asthma for at least 12 months
- 3) Existing treatment with low or medium ICS and other asthma therapies as reflected in GINA 2-4 steps
- 4) Participant or legally authorized representative (where applicable) has consented to participate
- 5) Participants must meet the criteria for at least one of the cohorts below: (A) asthma control cohorts: 1. ACQ-5 >= 1.5 (A1: uncontrolled cohort) 2. ACQ-5 < 1.5 (A2: controlled cohort); (B) Type-2 biomarker cohorts: 3. Elevated T2 biomarkers (B1: Type-2-high cohort) 4. Low T2 biomarkers (B2: Type-2-low cohort)
- Applicable for both Part 1 and Part 2 participants: 1) Current diagnosis of chronic obstructive pulmonary disease (COPD) or congestive heart failure
- 2) Participants with moderate/severe cognitive impairment.
- 3) Participants with moderate/severe cardiac disease.
- 4) Participants on immunosuppressive medication for a chronic condition
- 5) Participation in other interventional and noninterventional clinical study (currently or in the past 3 months)
The study team makes the final eligibility decision.
Where it's taking place
- France
- Germany
- China
- United Arab Emirates
- Japan
- United States
- Saudi Arabia
- Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include France; Germany; China; United Arab Emirates; Japan; United States and 2 more locations. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from EU CTIS. The study team decides eligibility, and your own doctor gives medical advice.